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Background and aim: CD24 expression is associated with human colorectal cancer (CRC). Our previous data
indicated that CD24 promoted the proliferation and invasion of colorectal cancer cells through the activation of
ERK1/2. Since Src family kinases are frequently deregulated in CRC and closely related to the MAPK signaling
pathway, we investigated the impact of Lyn, an important member of SFKs, on CD24-induced ERK1/2 activation in
CRC.
Methods and results: The interaction of CD24 and Lyn was identified by co-immunoprecipitation (Co-IP) and
ectopic expression of CD24-induced Lyn activation. Inhibition of Lyn activation by phosphatase PP2 in
SW480CD24cells abrogated CD24-induced invasion. The results of the Co-IP and immunofluorescence assay revealed
that overexpression of CD24 enhanced the interaction of Lyn and ERK1/2 and induced the nuclear translocation of
Lyn. However, inhibition of Lyn activity attenuated CD24-induced ERK1/2 activation, and depletion of CD24
disrupted Lyn-ERK1/2 interaction. Immunohistochemistry analysis for 202 cases of CRC showed that the expression
of both CD24 and Lyn was positively correlated with tumor grade, stage, lymph node and distant metastasis.
Patients with lower expression of CD24 or Lyn had a higher survival rate. The Cox multivariate analysis showed that
CD24 expression, but not Lyn expression, was an independent prognostic factor of CRC.
Conclusions: Our results suggest that Lyn is involved in CD24-induced ERK1/2 activation in CRC. The expression of
CD24 is associated with activation of Lyn and ERK1/2, which might be a novel mechanism related to
CD24-mediated regulation of CRC development.
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CD24, a small glycosyl-phosphoinositol-anchored mem-
brane protein ranging from 30–70 kDa, consists of a
small protein core comprising 27 amino acids, with sev-
eral potential O- or N-linked glycosylation sites [1].
CD24 has been identified to be up-regulated in various
solid tumors, such as breast cancer [2], prostate cancer
[3] and cholangiocarcinoma [4], and its overexpression
is usually associated with poor clinical outcomes in some
tumor types [2-4]. Chou et al. [5] reported strong cyto-
plasmic CD24 expression in diffuse- or mixed-type* Correspondence: helen2003517@163.com; drjiang@163.com
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reproduction in any medium, provided the orgastric adenocarcinomas. In addition, Sagiv et al. [6]
identified that increased expression of CD24 was an
early event in the carcinogenesis of colorectal cancer
(CRC). Our previous study also revealed that CD24 ex-
pression occurred in 92.5% of human CRC tissue and
increased with tumor progression [7]. Furthermore, we
showed that CD24 played an important role in the car-
cinogenesis of CRC.
CD24 is a short mucin-like peptide present at the
outer cell surface and lacks a cytoplasmic domain to
transduce intracellular signals. However, CD24 has been
identified as a novel regulator of proliferation [7], apop-
tosis [8] and invasion [9] in human cancer. Several
ligands of CD24, including P-selectin [10] and Siglec-10
[11], have been identified and are found to be crucial for
tumor development. In our previous study, we found
that the activation of extracellular signal-regulatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dependent of CD24 and required for the proliferation
[7] and invasion of CRC cells in vitro and in vivo (un-
published data). Although CD24 is an important player
in CRC, the mechanisms of its function in CRC remain
unclear. Exploring the mechanisms underlying CD24-
mediated activation of MAP kinases would be beneficial
in for better understanding of the role of CD24 in CRC
development.
To this end, the connection between CD24 and MAP
kinases in literature has been studied. Zarn et al. found
that CD24 localized in glycolipid-enriched membrane
(GEM) domains, which are the specialized areas in the
plasma membrane signaling platforms, and associated
with Lyn in an erythroleukemia cell line [12]. Moreover,
Petra et al. showed that CD24 interacted with c-Src and
promoted its activity within lipid rafts in breast cancer
cells [13]. Furthermore, many studies have suggested
that Src family kinases (SFKs) are located upstream of
MAPKs cascades in several receptor signaling systems
[14]. SFKs are a family of non receptor-type tyrosine
kinases and include at least nine highly homologous pro-
teins in mammals [15,16]. Lyn is an important member
of the SFKs and widely expressed in B-lymphocytes and
myeloid cells. Lyn establishes thresholds by acting as
both a positive and negative modulator of a variety of
signaling responses [17]. Furthermore, aberrant activa-
tion of Lyn has been implicated in variety of human
tumors, including breast cancer [18,19], prostate cancer,
glioblastoma and CRC [20,21]. Therefore, we hypothesize
that SFKs are involved in the CD24-induced ERK1/2 acti-
vation. In the present study, we examined the correlation
between CD24 and Lyn in CRC. Our results revealed that
CD24 interacted with Lyn and induced the activation and
nuclear translocation of Lyn. In contrast, the inactivation
of Lyn abrogated CD24-induced cell invasion and
ERK1/2 activation in CRC cells. Analysis of CRC tis-
sues with immunohistochemistry staining showed that
the expression of CD24 and Lyn was positively corre-
lated and associated with tumor stage and lymph
node and distant metastasis. Our study suggests that
the expression of CD24 is associated with the activa-
tion of Lyn and ERK1/2, which may be a novel mech-
anism related to CD24-mediated regulation of CRC
development.
Results
Lyn interacted with CD24 and was activated by CD24 in
CRC cells
To investigate the association of CD24 and SFKs, we exam-
ined the activation of SFKs, including Src, Lyn, Fyn and lck
in SW480CD24 cells and SW480 vector and parental cells.
The results showed that ectopic expression of CD24
increased the phosphorylation level of Lyn, but not Src, Fynor lck (Figure 1A), suggesting that CD24 specifically
induced the activation of Lyn, which is a signaling molecule
anchoring to plasma membrane. The densitometry results
of Figure 1A are shown in Additional file 1: Figure S1. To
determine whether there was an interaction between CD24
and Lyn, we performed a CO-IP assay. The results revealed
that endogenous or ectopic Lyn were co-precipitated with
CD24 in both SW480VEC and SW480CD24 cells when using
an anti-Lyn antibody. This interaction was also confirmed
in the reciprocal immunoprecipitation with anti-CD24 anti-
body (Figure 1B), indicating that endogenous CD24 was
capable of binding to Lyn, but binding was weaker than
that of the ectopic CD24. Furthermore, the increasing
amount of immuneprecipitates in SW480CD24 cells sug-
gested that the overexpression of CD24 might promote the
CD24-Lyn interaction in a direct or indirect manner. Con-
sistent with this observation, the depletion of CD24, using a
specific siRNA in SW620 cells, significantly reduced immu-
noprecipitates in the CO-IP assay (Figure 1C).
Ectopically expressed CD24 promoted cell invasion and
induced Lyn activation and translocation into the nucleus
We next examined the effect of ectopic expression of
CD24 by transfection with a pcDNA3.1(+)-CD24 expres-
sion plasmid [7] on the invasion capability of SW480
cells using a cell invasion kit. Invasion capability was
quantified as the percentage of invasive cells compared
to the total number cells. Representative images of inva-
sive cells of each group are shown in Figure 2A (upper,
original magnification, 200×). We observed a 2.15-fold
increase in cellular invasion in cells transfected with the
pcDNA3.1(+)-CD24 plasmid compared with the control
cells (Figure 2B) (p< 0.05). The expression levels of
CD24 and the phosphorylation of Lyn were assessed by
Western blot analysis. There was an increase in Lyn
phosphorylation (Y396) in SW480CD24 cells as compared
to SW480VEC cells (p< 0.05) (Figure 2C). To investigate
the role of Lyn in CD24-mediated cell invasiveness, cells
were treated with 10 μM PP2 and tested using a cell in-
vasion assay. The percentage of cells that migrated
through the filters from different groups was shown in
Figure 2A and B. Similar results were obtained in
SW620 cells (data not shown).
Since previous studies showed that distinct localization
of Lyn was critical for its function, the cellular
localization of Lyn was examined by analysis of dual im-
munofluorescence staining in this study. As shown in
Figure 2D, endogenous phospho-Lyn (green) in control
cells was weak and expressed throughout the entire cells
(left panels), whereas phospho-Lyn in CD24 expressing
cells was more prominent and more intense in the nu-
cleus (right panels). These findings suggested that CD24
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Figure 1 Interaction between CD24 and Lyn. A. Immunoblot analysis for phosphorylation levels of Src, Lyn, Fyn and lck in SW480CD24 and
vehicle control cells. GAPDH served as an internal control. All of these pictures were representatives of three independent experiments. B. The
interaction between Lyn and CD24 was examined in SW480CD24 (lane 2) and SW480VEC (lane 3) cells. Immunoprecipitation was performed with
an anti-CD24 antibody, and normal rabbit immunoglobulin G (Ig G) served as a control. Western blotting was performed with an anti-Lyn
antibody. Input (lane 1) is 1% of the extract from untreated cells. C. CD24 was depleted with CD24 specific siRNA in SW620 cells. Cell lysates were
immunoprecipitated with an anti-CD24 antibody and Western blotting was performed with anti-Lyn antibody.
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expression in human CRC tissues and cancer progression
To confirm the correlation between CD24 and Lyn
in vivo, immunohistochemical staining was performed in
serial sections of human CRC tissues. Lyn and CD24
staining were present mainly in the membrane and/or
cytoplasm (Figure 3) and were positively correlated
(r = 0.443, p< 0.05) (Table 1).
Immunohistochemical staining of the CRC tissue
showed that CD24 and Lyn had different degrees of
staining. For CD24 staining, 51% of the CRC tissues
showed positive and 49% showed moderate or strongly
positive staining, while its expression in adjacent normal
mucosa was either absent or barely detectable. For Lyn
staining, 56% of the CRC tissure showed positive and
44% showed moderately or strongly positive staining,
while its expression in adjacent normal mucosa was ei-
ther absent or barely detectable.
There was a significantly positive correlation between
CD24 expression and tumor grade, tumor stage, invasiondepth and lymph node and distant metastasis (p< 0.05),
while no correlation was observed between CD24 ex-
pression and age, sex, localization and tumor size (Figure
3 and Table 2). Lyn expression correlations were similar
to CD24 expression. Our results showed that CD24 and
Lyn expression increased with tumor progression.
Inactivation of Lyn inhibited CD24-induced ERK1/2
activation
In our previous study, we found that CD24 induced the
activation of ERK1/2 and p38 MAPK. To explore the
mechanism underlying CD24-induced ERK1/2 and p38
MAPK activation, PP2, a specific inhibitor of SFKs, was
used in this study. We exposed SW480CD24 cells to a
dose range of PP2, as indicated in Figure 4A, followed
by Western blot analysis of the phosphorylation of Lyn,
Erk1/2, and p38 MAPK.
Our data showed that the phosphorylation level of Lyn
and ERK1/2 decreased in PP2 treated SW480CD24 cells






























































Figure 2 Inhibition of Lyn activation attenuated CD24-induced CRC cell invasion. A. Representative images from the cell invasion assay.
SW480CD24 cells or vehicle control cells were seeded into transwell chambers coated with Matrigel and 10 μM PP2 was added 24 h later and kept
for 30 min. The cell invasion assay was performed at 24 h after PP2 treatment. CD24 increased the capacity of SW480 cells to migrate through
the filters compared with the controls cells (upper). Furthermore, the migration capacity of the SW480CD24 cells that were treated by PP2 (10 μM)
was inhibited (bottom). B. Quantification of cell invasion. Invasive activity was determined as the percent invasion of the control SW480 cells
through the Matrigel membrane. Values shown are means± standard errors (SE) for three independent experiments. * P< 0.05 between
SW480VEC and SW480CD24 cells; ** P< 0.05 between (SW480CD24 +DMSO) and (SW480CD24 + PP2) cells. C. Western blotting analysis showed the
phosphorylation of Lyn was induced by the over-expression of CD24 (lane 2) and the activation of Lyn was inhibited by PP2 (lane 4). GAPDH
served as a loading control. Bar graph depicted the quantitative analysis for protein expression and the expression of each protein was
normalized to GAPDH. D. Immunofluorescent staining of cells transfected with a pcDNA3.1(+)-CD24 plasmid. SW480 cells were transfected with a
CD24 expression plasmid or vehicle control. After 24 h, cells were fixed, permeabilized and stained with 4,6-diamidino-2-phenylindole (DAPI; blue)
and Lyn (green). In the cells with overexpressed CD24, Lyn was activated. phospho-Lyn was more intense in the nucleus.




Stage I Stage IV
Figure 3 The representative pictures of immunohistochemical
staining for Lyn and CD24 in serial sections of CRC tissues with
different stages (left: stage I; right: stage IV). (original
magnification = 400×). Lyn (upper) and CD24 (bottom) showed weak
expression in primary cancer tissues (stage I) and strong expression
in metastatic cancer tissues (stage IV).
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p38 MAPK was not impacted by PP2. The IC50 oc-
curred at 10 μM PP2 in the preliminary study (data not
shown); therefore, we chose 10 μM as a standard dose in
this study.
CD24 was depleted by a specific siRNA for CD24, which
led to the reduction of the phosphorylation of Lyn, ERK1/
2 and p38 MAPK in SW480CD24 cells (Figure 4B). CD24
specific siRNA and PP2 synergistically inactivated ERK1/
2, but not p38MAPK in both SW480CD24 (Figure 4B) and
SW620 cells (data not shown). We used another CD24
siRNA (CD24 siRNA-2) to confirm these data. CD24
siRNA-2 showed a similar effect (Additional file 1: Figure
S2). To identify the role of Lyn in the CD24-mediated
activation of ERK, Lyn was also depleted with a Lyn spe-
cific siRNA. The phosphorylation level of ERK1/2 was
dramatically decreased in Lyn depleted SW620 cells
(Figure 4C), suggesting that inactivation of Lyn could
attenuate CD24-induced ERK1/2 activation. Means ±
standard errors (SE) for three independent experiments
for Figure 4 are shown in Additional file 1: Figure S3.Table 1 The correlation of CD24 and Lyn expression in
202 CRC patients
CD24 Lyn r P
- + ++ +++
- 4 2 0 0 0.443 0.000
+ 6 72 12 8
++ 2 18 54 6
+++ 2 6 6 4Expression of ectopic CD24 enhanced the interaction of
Lyn and ERK1/2 and induced the nuclear translocation of
Lyn
SFKs are the upstream modulator of MAP kinases in
several receptor signaling pathways. To examine the
interaction of Lyn and ERK1/2, as well as the involved
regulation of CD24, CO-IP was performed for the inter-
action of Lyn and ERK. As shown in Figure 5A, the
interaction between Lyn and ERK1/2 was identified in
SW480CD24, but not in SW480VEC cells, indicating that
CD24 could enhance the binding of Lyn to ERK1/2. Our
data also showed that the interaction between Lyn and
ERK1/2 in SW620 cells, a CD24 abundant cell line, was
disrupted when CD24 was depleted by CD24 siRNA
(Figure 5B). These data supported the hypothesis that
Lyn interacted with ERK1/2 directly or indirectly in a
CD24-dependent manner. Furthermore, we examined
the effect of ectopically expressed CD24 on the location
of Lyn-ERK1/2. Nuclear accumulations of Lyn and
ERK1/2 were observed with an immunofluorescence mi-
croscopy in ectopic CD24 expressed cells (Figure 5C).The expression of CD24 and Lyn was associated with the
poor prognosis of CRC patients, and CD24 was an
independent prognostic factor of CRC
To investigate the prognostic value of CD24 and Lyn,
the association of CD24 and Lyn with an overall survival
was evaluated using Kaplan-Meier survival curves with
the log-rank test. Seventy-four CRC patients were en-
rolled for this analysis. The follow-up time ranged from
1 to 60 months. The median survival time of the group
with low expression of Lyn was 54.101 months, and the
cumulative 1-, 3- and 5-year survival rates were 90%,
85% and 83%, respectively. The median survival time of
the high expression group was 36.641 months, and the
1-, 3- and 5-year survival rates were 61%, 54% and 50%,
respectively. The difference between the groups was sig-
nificant. The median survival time of the group with low
expression of CD24 was 55.299 months, and the 1-, 3-
and 5-year survival rates were 95%, 91% and 86%, re-
spectively, while the survival rate of high expression
group was 36.324 months.
The univariate survival analysis indicated that the survival
rates of patients with low expression of CD24 (χ2=14.546,
P=0.000) or Lyn ( χ2 =12.559, P=0.000) was higher than
that of patients with high expression (log rank, P< 0.05;
Figure 6 and Table 3). Other factors that were associated
with tumor prognosis included tumor size, tumor stage,
and lymph node and distant metastasis (P< 0.05).
The Cox multivariate analysis showed that the expres-
sion of CD24 (P = 0.020, RR = 2.918, 95% CI: 1.188-
7.166), but not Lyn expression, could be used as an inde-
pendent prognostic factor. Our data also showed that
Table 2 Correlation of CD24 and Lyn expression and clinic-pathological parameters in 202 CRC patients
CD24 Lyn
Item Case - + ++ +++ Mean
ranks




Male 110 2 58 38 12 100.35 −0.336 0.737 9 54 38 9 98.92 −0.749 0.454
Female 92 4 40 42 6 102.87 5 44 34 9 104.59
*Age(years)
≤60 112 4 57 45 6 96.79 −1.407 0.159 8 56 40 8 99.14 −0.698 0.485
>60 90 2 41 35 12 107.36 6 42 32 10 104.43
#Localization
Right colon 32 1 15 14 2 101.44 0.02 0.990 2 19 8 3 93.44 1.217 0.544
Left colon 68 1 34 29 4 100.81 4 30 27 6 106.05
Rectum 102 4 49 37 12 101.98 8 49 37 9 101.04
*Tumor size
≤5 cm 155 4 78 58 15 100.82 −0.333 0.739 9 80 54 12 99.93 −0.759 0.448
>5 cm 47 2 20 22 3 103.76 5 18 18 6 106.69
&Grade
G1 99 3 58 34 4 0.255 0.000 6 58 30 5 0.233 0.000
G2 64 2 30 26 6 6 31 23 4
G3 39 1 10 20 8 2 9 19 9
&Tumor stage
I 30 2 22 6 0 0.577 0.000 3 20 5 4 0.399 0.000
II 85 2 62 20 1 8 59 17 3
III 50 1 12 32 5 2 12 31 3
IV 37 1 2 22 12 1 7 19 8
&Invasion depth
T1 38 2 24 10 2 0.293 0.000 5 22 9 2 0.297 0.000
T2 98 1 55 37 5 4 58 30 6
T3 44 2 17 22 3 4 16 20 4
T4 22 1 2 11 8 1 2 13 6
*Lymph node metastasis
Negative 130 5 84 38 3 82.70 −6.770 0.000 11 81 31 7 86.03 −5.516 0.000
Positive 72 1 14 42 15 135.44 3 17 41 11 129.43
*Distant metastasis
Negative 162 4 96 60 2 88.88 −6.805 0.000 13 89 52 8 92.71 −4.694 0.000
Positive 40 2 2 20 16 152.60 1 9 20 10 137.10
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1.475-13.105) and tumor stage (P = 0.019, RR = 2.289,
95% CI: 1.146 - 4.573) were also independent prognostic
factors for CRC patients (Table 4).
Discussion
It is reported that SFKs are over-expressed and activated
in a large number of human malignancies. SFKs have
been found to be associated with the development of
cancer and progression to distant metastasis, includingCRC [18,21]. More interesting, GPI-anchored proteins-
related signaling transduction is also mediated by SFKs
[22]. In our previous study, we found that ERK1/2 was
involved in CD24-induced CRC cell proliferation [7] and
invasion. In the present study, we aimed to investigate
the role of SFKs in this cellular process. Therefore, we
first detected the effects of CD24 on the activity of SFKs
in CRC cells by Western blotting. We found that CD24
could increase the expression of phospho-Lyn (Y396),


























Figure 4 CD24-induced ERK1/2 activation was regulated by the activation of Lyn. A. SW480CD24 cells were treated with increasing doses of
PP2 (0 μM, 5 μM, 10 μM, and 20 μM) for 30 min and the medium was renewed. Cell lysates were prepared 24 h later after treatment, and the
level of phospho-Lyn, phospho-ERK and phospho-p38 MAPK were measured by Western blot analysis. The decreased expression peaked at 20 μM
PP2 (lane 4) and the dose of 10 μM PP2 was selected for further studies. B. SW480CD24 cells were transfected with vehicle control (NCsiRNA) or
CD24 specific siRNA 24 h prior to PP2 (10 μM) treatment. The cells were treated with PP2 for 30 min and harvested 24 h after treatment. The
expression of CD24, as well as the level of phospho-Lyn, phospho-ERK1/2 and phospho-p38 MAPK, was assessed by Western blot analysis. C.
SW620 cells were transfected with vehicle control (NCsiRNA) or Lyn specific siRNA and lysed 24 h after treatment. ERK1/2 phosphorylation was
assessed by Western blot analysis.
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duction. Three research groups [12,23,24] reported that
CD24 interacted with Lyn directly or indirectly in mono-
cytic ESb-MP cells, in the erythroleukaemia cell line
K562 and in the Burkitt’s lymphoma (BL)-derived cell
line P32/SH. Therefore, we hypothesized that there was
an interaction between CD24 and Lyn directly or indir-
ectly in CRC. Through CO-IP assays, we identified this
interaction in CRC, and this might be the first report ofan interaction between CD24 and Lyn in solid tumors.
To identify the interaction between CD24 and Lyn
in vivo, we examined the expression of CD24 and Lyn
by immunohistochemical staining on serial sections of
CRC tissues. The results showed that the expression of
CD24 was positively correlated with phospho-Lyn ex-
pression in 202 CRC patients.
Mierke et al. found that CD24 enhanced human lung














Figure 5 The interaction between Lyn and ERK1/2. A. The interaction between Lyn and ERK1/2 was detected in SW480CD24 and SW480VEC
cells. Cell lysates were immunoprecipitated by an anti-Lyn antibody and assayed by Western blotting with an anti-ERK1/2 antibody. Normal rabbit
IgG served as a control. B. SW620 cells were transiently transfected with CD24 siRNA. Cell lysates were immunoprecipitated by an anti-Lyn
antibody and assayed by Western blotting analysis with a ERK1/2 antibody. Pictures are representatives of two or three independent experiments
with identical results. C. Immunofluorescent staining of SW620 cells transfected with CD24 siRNA. SW620 cells were transiently transfected with
CD24siRNA or vehicle control for 24 h. Cytosolic and nucleus location of Lyn (green) and ERK1/2 (red) were examined by primary antibodies
followed by FITC-conjugated secondary antibodies and visualized under fluorescent microscopy (original magnification= 630×, Oil). The nucleus
was stained with 4, 6-diamidino-2-phenylindole (DAPI; blue). phospo-Lyn and phospho-ERK1/2 signals were greater and intense in the nucleus.
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study, we also found that overexpression of CD24 could
increase the cell invasion ability. Furthermore, we inves-
tigated the role of Lyn in CD24- induced CRC cell inva-
sion. After treating cells with PP2, a specific inhibitor of
SFKs, CD24-induced CRC cell invasion was abrogated,
suggesting that Lyn was involved in CD24-induced cell
invasion. SFKs are known to be ubiquitously distributed
in the cell membrane, but Src is located in perinuclear
membranes, endosomes and possibly even the nucleus,
implicating the involvement of Src in nuclear-signal
transduction events [26]. The regulation of nucleocyto-
plasmic distribution of Lyn contributes to the associ-
ation of Lyn with other upstream or downstream
signaling molecules. To elucidate the underlying
mechanisms in this process, we examined the subcellular
localization of Lyn by immunoflourescence staining. In
SW480VEC cells, positive cellular signals of Lyn was pre-
dominant in the cytoplasm, and over-expression of
CD24 resulted in a cytosolic decrease and a nuclear ac-
cumulation of Lyn. The nuclear translocation strongly
implied that the regulation of gene transcription of Lynmight be involved, which should be clarified in further
studies. In addition, we found that Lyn and CD24 were
expressed in different tumor stages of CRC and the ex-
pression level of CD24 and Lyn was positively correlated
with tumor grade, tumor stage, invasion depth, and
lymph node and distant metastasis.
SFKs are the upstream modulator of MAP kinases in
several receptor signaling pathways. Therefore, it is pos-
sible that CD24 directly or indirectly interacts with Lyn
and affects the activity of ERK1/2. We found that the de-
pletion of CD24 and Lyn, by specific siRNA or inactiva-
tion of Lyn by its specific inhibitor PP2, could reduce
the phosphorylation level of ERK1/2 respectively or syn-
ergistically. CO-IP assays showed that Lyn interacted
with ERK1/2 in a CD24 high expression cell line and the
Lyn-ERK interaction was disrupted by the depletion of
CD24, suggesting that Lyn was involved in CD24-
induced ERK1/2 activation in CRC cells. Therefore, it is
possible that CD24 directly or indirectly induces the ac-
tivation of Lyn and promotes the interaction and nuclear
translocation of Lyn, leading to cell invasion. To better
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Figure 6 Kaplan-Meier survival curves of 74 CRC patients relating to the status of CD24 (A) and Lyn (B) expression. The log-rank test
was used to calculate P values (CD24: P = 0.020).
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characterize the interaction site or structure among
CD24, Lyn and ERK1/2 on the membrane, such as
glycolipid-enriched membrane (GEM) domains or
nucleus.
The studies on the roles of CD24 and Lyn in CRC in-
vasion provided potential targets for CRC diagnosis and
prognosis. However, the clinicopathologic significance of
CD24 is still controversial [7,27,28] and very few studies
have elucidated the relationship between Lyn and clini-
copathological characteristics of CRC. Sagiv et al. [6]
showed that CD24 was expressed in 90.7% of adenomas
and 86.3% of CRC. In addition, recent studies suggested
that CD24 was a promising therapeutic target in cancers
of the gastrointestinal tract and bladder cancer metasta-
sis [29-31]. In our study, strong expression of cytoplas-
mic CD24 correlated significantly to shortened survivalof CRC patients without distant metastases [28]. How-
ever, studies from Ahmed et al. [32] and Choi et al. [33]
showed early CD24 up-regulation and nuclear expres-
sion, but it was not a prognostic marker for CRC. Hao
et al. [21] showed that Lyn was significantly correlated
with overall survival in CRC patients. In the present
study, the Cox multivariate analysis showed that CD24,
tumor distant metastasis and tumor stage were inde-
pendent prognostic factors of CRC patients. In contrast,
Lyn was not an independent prognostic factor of CRC,
which is different from previously reported studies.
In this study, we showed that Lyn was involved in
CD24-induced ERK1/2 activation and CRC cell invasion
in vitro. In vivo, we found aberrant CD24 and Lyn ex-
pression in the majority of the CRC tissues and a signifi-
cant correlation between CD24 and Lyn. CD24 was
identified as an independent prognostic factor of CRC,
Table 3 Univariate survival analysis of 74 CRC patients
Factors Case (n) χ2 P
Sex
Males 45/15 0.027 0.869
Female 29/10
Age
≤60y 37/13 0.103 0.748
>60y 37/12
Localization




≤5cm 50/21 4.777 0.029
>5cm 24/4
Grade














Negative 42/8 13.972 0.000
Positive 32/17
Distant metastasis
Negative 55/10 50.535 0.000
Positive 19/15
CD24
low 42/7 14.456 0.000
high 32/18
Lyn
low 44/8 12.559 0.000
high 30/17
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vation of Lyn and ERK1/2, which might be a novel
mechanism related to CD24-mediated regulation of CRC
development.Materials and methods
Reagents and antibodies
RPMI-1640 medium and FBS were purchased from Life
Technologies (Grand Island, NY). G418 was obtained from
Calbiochem (San Diego, CA). The PP2 inhibitor was pur-
chased from Sigma (St. Louis, MO). ERK1/2 (137 F5),
phospho-ERK1/2 (Thr202/Tyr204), p38 MAPK, phospho-
p38 MAPK (Thr180/Tyr186), SAPK/JNK, phospho-SAPK/
JNK (Thr183/Tyr185), Lyn (C13F9), Src, and phospho-Src
(TYR416) antibodies were purchased from Cell Signaling
Technology (Danvers, MA). The phospho-Lyn (Y396) anti-
body was purchased from Abcam (Cambridge, MA). CD24
(C-20), GAPDH, phospho-Fyn (Thr12), Fyn, phospho-lck
(Tyr394) and lck antibodies, FITC-antibody, and Lyn
siRNA were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA).
Tissue samples
Formalin-fixed, paraffin-embedded tissue samples from
202 (110 men and 92 women) primary CRC patients
were randomly obtained and processed by routine clin-
ical histopathological methods. The patients had a mean
age of 57 years (range 18-87 years) and a median age of
59 years. The pathological tumor stages were determined
according to the TNM classification of the American
Joint Committee on Cancer Criteria, and the World
Health Organization (WHO) classification of tumors
was used to determine the histological grade. Clinical
follow-up data were available for 74 patients, while 128
patients were excluded for lack of information. The
study was carried out in accordance with the institu-
tional ethical guidelines and was approved by the
Medical Ethics Committee of Southern Medical Univer-
sity. Informed consent was obtained from all patients.
Cell culture and treatments
SW480 and SW620 cell lines were obtained from Ameri-
can Type Culture Collection (Rockville, MD). SW480CD24
and SW480VEC cells were established, as described in a
previous study [7]. Cells were maintained in RPMI-1640
medium supplemented with 10% FBS (complete medium)
and 1000 μg/ml G418 at 37°C with an atmosphere of 5%
CO2 and subcultured by digestion with 0.05% trypsin. For
PP2 treatment, cells were seeded in serum-free medium
overnight, followed by the addition of PP2 as indicated for
30 min at 37°C. Medium containing the PP2 inhibitor was
renewed after 30 min of incubation.
RT-PCR
Total RNA was isolated from cells using Trizol (Invi-
trogen). Next, 2 μg of RNA sample was subjected to
reverse transcription using a RevertAid First Strand
cDNA Synthesis Kit (K1622, Fermentas, MBI, Vilnius,
Lithuania). The primer pairs for CD24 were 5'-
Table 4 Multivariate analysis of prognostic factors in 74 CRC patients
B SE Wald df P RR 95.0 % CI for Exp(B)
Lower Upper
Tumor stage 0.828 0.353 5.499 1 0.019 2.289 1.146 4.573
Distant Metastasis 1.481 0.557 7.059 1 0.008 4.396 1.475 13.105
CD24 1.071 0.458 5.456 1 0.020 2.918 1.188 7.166
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and 5'-CCGGAATTCCGTTAAGAGTAGAGATGC-3' (re-
verse). The primer pairs for GAPDH were 5’-
GTCAACGGATTTGGTCGTATTG-3’ (forward) and 5’-
CTCCTGGAAGATGGTGATGGG-3’ (reverse). PCR was
initiated by 5 min incubation at 94°C, 36 cycles of denatur-
ation at 94°C for 45 s, annealing at 56°C and extension at
72°C for 50 s, and ended after a 7 min extension at 72°C
using a PCR kit (SBS, Beijing, China). The experiments
were repeated twice and GAPDH mRNA was amplified
simultaneously as an internal control.Preparation of siRNA and transfection
A siRNA duplex targeting CD24 and a negative control
sequence were designed and synthesized by GenePharma
Co. (Shanghai, China). The target sequence of the CD24
siRNA duplex was as follows: CD24 siRNA sense 5'-
GAUUUAUUCCA GUGAAACATT-3' and antisense 5'-
UGUUUCACUGGAAUA AAUCTG-3'. The negative
control sequence was as follows: sense 5'-CUACCUA
UGCAGAUUU AUUdTdT-3' and antisense 5'-AAUAAA
UCUGCAUAGGUAGdTdT-3'. BLAST research con-
firmed the unique sequence of the siRNA. Lyn siRNA
was purchased from Santa Cruz Biotechnology (sc-
29393, Santa Cruz, CA). The specific and negative con-
trol siRNAs were transfected into SW480CD24 and/or
SW620 cells 24 h prior to Western blotting analyses or
cell invasion assays using lipofectamineTM 2000 reagent
according to the manufacturer’s instructions.Western blotting analysis
Whole cell lysates were prepared as described previously
[34]. Equal aliquots of total cell lysates (30 μg) were elec-
trophoresed on denaturing sodium dodecy1 sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels (5%
stacking gel and 8%-12% resolving gel). The proteins were
then transferred to polyvinylidene difluoride (PVDF)
membranes (Millipore, Bedford, MA). The blots were
probed with primary antibodies followed by the horserad-
ish peroxidase-conjugated secondary antibody. Antigen-
antibody complexes were visualized using an enhanced
chemiluminescence system (Amersham Biosciences, Little
Chalfont Buchkinghamshire, UK). GAPDH served as the
loading control.Immunofluorescence
Immunofluorescent staining was performed as described
[35]. In brief, cells grown on cover glass were fixed in
phosphate-buffered saline (PBS) containing 4% parafor-
maldehyde for 30 min at room temperature. Nonspecific
binding was blocked by incubation with 1% bovine serum
albumin (BSA). Cells were subsequently reacted with an
appropriate primary antibody for 1 h, then washed and
stained with TR-or fluorescein isothiocyanate-conjugated
second antibodies. After mounting with Prolong Antifade™
reagent (Molecular Probes), the cells were visualized
under an Olympus CKX41 fluorescence microscope
(Olympus, Tokyo, Japan).
Co-IP
As described previously [36], 2 mg of cell lysates from
control or transfected cells were incubated with 3 μg of
primary antibody overnight at 4°C on an oscillation
shaker. Then, 50 μl of suspension, with a 1:1 ratio of
protein A-Sepharose beads, were added and incubated
for 2 h at 4°C with gentle rotation. After extensive wash-
ing, precipitates were subjected to Western blotting ana-
lyses for detection of potential interacting proteins.
Normal rabbit IgG served as a negative control.
Cell invasion assay
Cell invasion was assessed using an invasion assay kit
(ECM551, Millipore, Bedford, MA) [37] according to
manufacturer’s instructions. The cells, which were
treated according to different experimental purposes,
were suspended in serum free RPMI-1640 medium at
a density of 1.0 × 106/ml. Next, 300 μl of the prepared
cell suspension and 500 μl of RPMI-1640 containing
10%FBS were respectively added in each insert and
the matched lower chamber and incubated for add-
itional 24 h. Non-invaded cells were removed with
cotton swabs. Invasive cells were stained with 0.2%
crystal violet and counted under a microscope. Six
random fields for each insert were counted (per
HPF × 200).
Immunohistochemical analysis and evaluation
The Medical Ethics Committee of Southern Medical
University approved our experimental protocols.
Paraffin-embedded tissue blocks were cut into 4 μm
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deparaffinized with xylene, rehydrated with ethanol,
washed, and subjected to microwave retrieval in a citrate
buffer. Sections were then immersed in 3% hydrogen
peroxide to block endogenous peroxidase activity and
incubated with primary antibodies at 4°C overnight fol-
lowed by incubation with goat or rabbit serum for
30 min the next day. Subsequent steps utilized the Ultra-
SensitiveTM SP kit (KIT-0310, Maxin_bio, Fuzhou,
China) according to the manufacturer’s instructions. The
expressions of CD24 and Lyn were visualized using DAB
and counterstained with hematoxylin. Tissues were con-
sidered “positive” when 10% or more of the cancer cells
were positively stained [38]. For quantitative analysis,
the ratio of positively stained cells to all tumor cells in
five random areas at 200X and/or 400X magnification
was recorded.
Statistical analysis
Statistical analysis was performed using the software
package SPSS 13.0. ANOVA provided a statistical test
used to determine the results of cell invasion assay.
Non-parametric Kruskal-Wallis or Mann–Whitney
tests were used to test the differences between sub-
groups of clinic-pathological parameters, whereas the
correlations of the expression of different proteins
were evaluated by the Spearman rank-order correlation
coefficient. Kaplan-Meier and Log-rank tests analyzed
the univariate prognostic analysis, qualifying into the
COX proportional hazards model for multivariate ana-
lysis. The level of significance was defined as P< 0.05.
Additional file
Additional file 1: Supplementary figures. Figure S1: Densitometry
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